Rezera, a Phase 3-ready biotech developing oral NLRP3 inhibitors for inflammatory diseases, postponed its IPO on Thursday. It had filed to raise $200 million by offering 16.7 million shares at a price range of $11 to $13. New investor and affiliate GSK had indicated on up to $25 million of the IPO (13% of the deal).
The Boston, MA-based company was founded in 2016. It had planned to list on the Nasdaq under the symbol RZRA. Jefferies, TD Securities, and Cantor Fitzgerald were set to be the joint bookrunners on the deal.
